NCT03836053 - Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

April 21, 2022

Study Completion Date

April 21, 2022

Conditions

Relapsed and/or Refractory Multiple Myeloma

Interventions

DRUG

AMG 420

28 day continuous Intravenous infusion of either 400 mcg/d or 600 mcg/d followed by 2 treatment free weeks

Trial Locations (10)

St Vincents Hospital Sydney, Darlinghurst

St Vincents Hospital Melbourne, Fitzroy, VIC

Centre Hospitalier Universitaire Dinant Godinne - Universite Catholique de Louvain Namur, Yvoir

Centres Hospitaliers Jolimont - Hopital de Jolimont, Haine Saint Paul - La Louviere

Kantonsspital St Gallen, Sankt Gallen

Memorial Sloan Kettering Cancer Center, New York

Wake Forest Baptist Health, Winston-Salem

Advocate Lutheran General Hospital, Park Ridge

Massachusetts General Hospital, Boston

National Hospital Organization Okayama Medical Center, Okayama